Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results | Zendy

Gooitzen M. van Dam | Zendy; George Themelis | Zendy; Lucia M. A. Crane | Zendy; Niels J. Harlaar | Zendy; Rick G. Pleijhuis | Zendy; Wendy Kelder | Zendy; Athanasios Sarantopoulos | Zendy; Johannes S. de Jong | Zendy; Henriëtte J.G. Arts | Zendy; Ate G.J. van der Zee | Zendy; Joost Bart | Zendy; Philip S. Low | Zendy; Vasilis Ntziachristos | Zendy

Open Access

Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results

Author(s) -

Gooitzen M. van Dam,

George Themelis,

Lucia M. A. Crane,

Niels J. Harlaar,

Rick G. Pleijhuis,

Wendy Kelder,

Athanasios Sarantopoulos,

Johannes S. de Jong,

Henriëtte J.G. Arts,

Ate G.J. van der Zee,

Joost Bart,

Philip S. Low,

Vasilis Ntziachristos

Publication year - 2011

Publication title -

nature medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.536

H-Index - 547

eISSN - 1546-170X

pISSN - 1078-8956

DOI - 10.1038/nm.2472

Subject(s) - ovarian cancer , debulking , folate receptor , medicine , cancer , stage (stratigraphy) , fluorescence lifetime imaging microscopy , tumor debulking , cancer research , oncology , pathology , cancer cell , fluorescence , chemotherapy , biology , physics , quantum mechanics , paleontology

The prognosis in advanced-stage ovarian cancer remains poor. Tumor-specific intraoperative fluorescence imaging may improve staging and debulking efforts in cytoreductive surgery and thereby improve prognosis. The overexpression of folate receptor-α (FR-α) in 90-95% of epithelial ovarian cancers prompted the investigation of intraoperative tumor-specific fluorescence imaging in ovarian cancer surgery using an FR-α-targeted fluorescent agent. In patients with ovarian cancer, intraoperative tumor-specific fluorescence imaging with an FR-α-targeted fluorescent agent showcased the potential applications in patients with ovarian cancer for improved intraoperative staging and more radical cytoreductive surgery.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research